387 related articles for article (PubMed ID: 20416024)
1. Trial of aripiprazole in the treatment of first-episode schizophrenia.
Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
4. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
6. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
7. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
Kim CY; Chung S; Lee JN; Kwon JS; Kim DH; Kim CE; Jeong B; Jeon YW; Lee MS; Jun TY; Jung HY
Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
[TBL] [Abstract][Full Text] [Related]
8. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
[TBL] [Abstract][Full Text] [Related]
9. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Kane JM; Meltzer HY; Carson WH; McQuade RD; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
[TBL] [Abstract][Full Text] [Related]
14. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
Riedel M; Spellmann I; Schennach-Wolff R; Musil R; Dehning S; Cerovecki A; Opgen-Rhein M; Matz J; Seemüller F; Obermeier M; Severus E; Engel RR; Müller N; Möller HJ
Pharmacopsychiatry; 2010 Mar; 43(2):50-7. PubMed ID: 20336597
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
[TBL] [Abstract][Full Text] [Related]
16. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
Pae CU; Serretti A; Chiesa A; Mandelli L; Lee C; Lee C; Kim J; De Ronchi D; Paik IH
Eur Neuropsychopharmacol; 2009 Aug; 19(8):562-70. PubMed ID: 19442491
[TBL] [Abstract][Full Text] [Related]
17. Intramuscular aripiprazole in the acute management of psychomotor agitation.
De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P
Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
[TBL] [Abstract][Full Text] [Related]
19. Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series.
Chen CY; Lin TY; Wang CC; Shuai HA
Psychiatry Clin Neurosci; 2011 Feb; 65(1):95-7. PubMed ID: 21265942
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial.
Takahashi H; Oshimo T; Ishigooka J
Clin Neuropharmacol; 2009; 32(3):149-50. PubMed ID: 19483480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]